Sustained virologic response to second-generation direct-acting antivirals for Hepatitis C
Background: Recently, the management of patients chronically infected with the hepatitis C virus has progressed, including second generation direct-acting antivirals (DAA) that have potential to clear infection in most patients, especially genotype 1-infected patients. Objectives: Evaluate the susta...
| Autores: | , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2020 |
| País: | Brasil |
| Institución: | Secretaria de Estado da Saúde de São Paulo (SES-SP) |
| Repositorio: | BEPA. Boletim epidemiológico paulista (Online) |
| Idioma: | portugués |
| OAI Identifier: | oai:ojs.periodicos.saude.sp.gov.br:article/33949 |
| Acceso en línea: | https://periodicos.saude.sp.gov.br/BEPA182/article/view/33949 |
| Access Level: | acceso abierto |
| Palabra clave: | Hepatite C crônica Estudo observaciona Tratamento Genótipo Resposta virológica sustentada Chronic Hepatitis C Observational study Treatment Genotype Sustained virologic response |
| Sumario: | Background: Recently, the management of patients chronically infected with the hepatitis C virus has progressed, including second generation direct-acting antivirals (DAA) that have potential to clear infection in most patients, especially genotype 1-infected patients. Objectives: Evaluate the sustained virologic response (SVR) of Hepatitis C treatment with second-generation DAAs made available by the Ministry of Health in follow-up patients of a São Paulo health service. Methods: This was a retrospective observational study, based on secondary data obtained from GAL and MEDEX systems. Briefly, 615 convenience samples were analyzed of patients who underwent second-generation DAAs treatment from June 2016 to April 2018. Demographic and clinical data were also analyzed. Results: SVR was observed in 600 treated patients (97.6%). Further, 98.4% and 94.7% of genotype 1 and genotype 3 patients, respectively, responded to treatment (P = 0.02). Among patients who did not respond to treatment, 93.3% were male, naive treatment and were treated for 12 weeks, except one genotype 1, HIV-coinfected patient who received treatment for 24 weeks. Conclusions: A high rate of SVR was found for Hepatitis C treatment with second-generation DAAs. SVR was significantly reduced in male and genotype 3-infected patients, although it still exceeded 90%. Further, HIV coinfection showed no association with reduced SVR rates (p=0.98). |
|---|